Vero biotech is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions. At Vero Biotech, our mission is to improve the lives of patients by leading the development of innovative technologies for inhaled NO delivery in the acute care hospital setting and beyond, wherever Nitric Oxide treatment is needed. We strive to exceed customer expectations in terms of safety, efficacy, and growth by focusing on the science, development, and commercialization of our innovations.
$30M sweet spot round size
$30M
from 1 investors over 1 rounds
VERO Biotech raised $30M on February 11, 2023
Investors: Petrichor Healthcare Capital Management